Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Hematopoietic stem cell transplantation (HCT) activity in Europe showed a slight slowdown in 2022, with a notable increase in CAR-T cell therapies despite a decrease in overall allogeneic and autologous HCT procedures.
Area Of Science
- Hematology
- Oncology
- Cellular Therapy
Background
- Hematopoietic stem cell transplantation (HCT) is a crucial treatment for various hematologic, oncologic, and non-malignant disorders.
- European HCT activity data provides insights into treatment trends and resource allocation.
Purpose Of The Study
- To analyze the trends in HCT and advanced cellular therapies in Europe for 2022.
- To identify changes in HCT indications, donor types, and the utilization of CAR-T cells.
Main Methods
- Retrospective analysis of HCT and CAR-T therapy data from 689 European centers in 2022.
- Comparison of 2022 data with previous years to identify trends.
Main Results
- A total of 46,143 HCT procedures were performed in 41,854 patients.
- CAR-T cell therapy use increased by 27%, while allogeneic and autologous HCT decreased by 4.0% and 1.7%, respectively.
- Myeloid malignancies were the primary indication for allogeneic HCT, while lymphomas and PCD were key for autologous HCT.
Conclusions
- European HCT activity growth has slowed, with a significant rise in CAR-T cell therapies.
- Decreased use of HCT for lymphoid malignancies may reflect the impact of novel therapies.
- Pediatric HCT activity remained stable, but CAR-T use varied significantly across European countries.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...